Ethambutol

CAS# 74-55-5

Ethambutol

Catalog No. BCC5195----Order now to get a substantial discount!

Product Name & Size Price Stock
Ethambutol: 5mg Please Inquire In Stock
Ethambutol: 10mg Please Inquire In Stock
Ethambutol: 20mg Please Inquire Please Inquire
Ethambutol: 50mg Please Inquire Please Inquire
Ethambutol: 100mg Please Inquire Please Inquire
Ethambutol: 200mg Please Inquire Please Inquire
Ethambutol: 500mg Please Inquire Please Inquire
Ethambutol: 1000mg Please Inquire Please Inquire
Related Products
  • BMS-303141

    Catalog No.:BCC4097
    CAS No.:943962-47-8

Quality Control of Ethambutol

Number of papers citing our products

Chemical structure

Ethambutol

3D structure

Chemical Properties of Ethambutol

Cas No. 74-55-5 SDF Download SDF
PubChem ID 14052 Appearance Powder
Formula C10H24N2O2 M.Wt 204.31
Type of Compound N/A Storage Desiccate at -20°C
Synonyms Emb
Solubility Soluble in DMSO
Chemical Name (2S)-2-[2-[[(2S)-1-hydroxybutan-2-yl]amino]ethylamino]butan-1-ol
SMILES CCC(CO)NCCNC(CC)CO
Standard InChIKey AEUTYOVWOVBAKS-UWVGGRQHSA-N
Standard InChI InChI=1S/C10H24N2O2/c1-3-9(7-13)11-5-6-12-10(4-2)8-14/h9-14H,3-8H2,1-2H3/t9-,10-/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Ethambutol

DescriptionEthambutol is a bacteriostatic antimycobacterial agent, which obstructs the formation of cell wall by inhibiting arabinosyl transferases. Target: Antibacterial Ethambutol directly affects two polymers, arabinogalactan (AG) and lipoarabinomannan (LAM) in Mycobacterium smegmatis. In M. smegmatis, Ethambutol inhibits synthesis of arabinan completely and inhibits AG synthesis most likely as a consequence of this; more than 50% of the cell arabinan is released from the bacteria following Ethambutol treatment, whereas no galactan is released. Ethambutol main targets against embB gene product in M. avium. Ethambutol induces 60% changes in the embB gene in M. tuberculosis resistant mutants [1]. Ethambutol is effective against actively growing microorganisms of the genus Mycobacterium, including M. tuberculosis. Nearly all strains of M. tuberculosis and M. kansasii as well as a number of strains of the M. aviumcomplex (MAC) are sensitive to Ethambutol. [1] Ethambutol is potency against M. tuberculosis (H37Rv) with MIC of 0.5 μg/mL in vitro [2]. Ethambutol is efficient on treatment of mycobacterial-infected macrophages. When M. tuberculosis infected macrophages are treated with 6 μg/mL Ethambutol, the log CFUs following treatment for 3 days is 4.17, while value in control group is 4.8. The MICs for M. avium (MTCC 1723) and M. smegmatis (MTCC 6) are 15 μg/mL and 0.18 μg/mL, respectively. Ethambutol is efficient in animal model. 100 mg/kg Ethambutol given orally 15 days post i.v. infection 1 ×/week for 5 weeks, induces a lower log CFU compared with untreatment (4.59 vs 5.07) [3].

References:
[1]. Ethambutol. Tuberculosis (Edinb), 2008. 88(2): p. 102-5. [2]. Rastogi, N., V. Labrousse, and K.S. Goh, In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain [3]. Kaur, D. and G.K. Khuller, In vitro, ex-vivo and in vivo activities of ethambutol and sparfloxacin alone and in combination against mycobacteria. Int J Antimicrob Agents, 2001. 17(1): p. 51-5.

Ethambutol Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Ethambutol Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Ethambutol

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 4.8945 mL 24.4726 mL 48.9452 mL 97.8905 mL 122.3631 mL
5 mM 0.9789 mL 4.8945 mL 9.789 mL 19.5781 mL 24.4726 mL
10 mM 0.4895 mL 2.4473 mL 4.8945 mL 9.789 mL 12.2363 mL
50 mM 0.0979 mL 0.4895 mL 0.9789 mL 1.9578 mL 2.4473 mL
100 mM 0.0489 mL 0.2447 mL 0.4895 mL 0.9789 mL 1.2236 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Ethambutol

Ethambutol is a bacteriostatic antimycobacterial agent, which obstructs the formation of cell wall by inhibiting arabinosyl transferases.

Featured Products
New Products
 

References on Ethambutol

The rare ethambutol-induced optic neuropathy: A case-report and literature review.[Pubmed:28079833]

Medicine (Baltimore). 2017 Jan;96(2):e5889.

RATIONALE: Ethambutol-induced optic neuropathy (EON) is a well-known complication that results from the use of Ethambutol. The ocular manifestations of EON include painless loss of central vision and cecocentral scotomas in the visual field. PATIENT CONCERNS: A 75-year-old Chinese Han man suffered from this rare ocular disorder because he took Ethambutol for about 8 months. DIAGNOSES: He was diagnosed as EON based on series of ophthalmic examinations performed. INTERVENTIONS: Since he has stopped taking this drug for 3 months, we just offered some neurotrophic agents to him. OUTCOMES: One month later, he came back for return visit. The ophthalmic examinations indicated recovery of the visual function very well. LESSONS: The EON is a reversible optic neuropathy if the ocular toxicity is monitored closely among the tuberculosis patients that take Ethambutol.

The Antituberculosis Drug Ethambutol Selectively Blocks Apical Growth in CMN Group Bacteria.[Pubmed:28174310]

MBio. 2017 Feb 7;8(1). pii: mBio.02213-16.

Members of the genus Mycobacterium are the most prevalent cause of infectious diseases. Mycobacteria have a complex cell envelope containing a peptidoglycan layer and an additional arabinogalactan polymer to which a mycolic acid bilayer is linked; this complex, multilayered cell wall composition (mAGP) is conserved among all CMN group bacteria. The arabinogalactan and mycolic acid synthesis pathways constitute effective drug targets for tuberculosis treatment. Ethambutol (EMB), a classical antituberculosis drug, inhibits the synthesis of the arabinose polymer. Although EMB acts bacteriostatically, its underlying molecular mechanism remains unclear. Here, we used Corynebacterium glutamicum and Mycobacterium phlei as model organisms to study the effects of EMB at the single-cell level. Our results demonstrate that EMB specifically blocks apical cell wall synthesis, but not cell division, explaining the bacteriostatic effect of EMB. Furthermore, the data suggest that members of the family Corynebacterineae have two dedicated machineries for cell elongation (elongasome) and cytokinesis (divisome). IMPORTANCE: Antibiotic treatment of bacterial pathogens has contributed enormously to the increase in human health. Despite the apparent importance of antibiotic treatment of bacterial infections, surprisingly little is known about the molecular functions of antibiotic actions in the bacterial cell. Here, we analyzed the molecular effects of Ethambutol, a first-line antibiotic against infections caused by members of the genus Mycobacterium We find that this drug selectively blocks apical cell growth but still allows for effective cytokinesis. As a consequence, cells survive Ethambutol treatment and adopt a pneumococcal cell growth mode with cell wall synthesis only at the site of cell division. However, combined treatment of Ethambutol and beta-lactam antibiotics acts synergistically and effectively stops cell proliferation.

Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trial.[Pubmed:28193240]

Trials. 2017 Feb 13;18(1):68.

BACKGROUND: Linezolid, an oxazolidinone, substantially improves treatment outcomes of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. We started a trial to test whether the use of linezolid instead of Ethambutol could increase the rate of sputum culture conversion as of 8 weeks of treatment in patients with drug-susceptible tuberculosis. METHODS/DESIGN: This is a phase II, multicenter, randomized study with three arms. We are enrolling patients with pulmonary tuberculosis without rifampicin resistance screened by the Xpert MTB/RIF(R) assay. The standard treatment arm uses isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and Ethambutol (2 months). Experimental arm 1 uses linezolid (600 mg/day) for 4 weeks instead of Ethambutol. Experimental arm 2 uses linezolid (600 mg/day) for 2 weeks instead of Ethambutol. The primary outcome is the sputum culture conversion rate on liquid media after 2 months of treatment. Secondary outcomes include the sputum culture conversion rate on solid media after 2 months of treatment, time to sputum culture conversion on liquid and solid media, cure rate, and treatment success rate. The frequencies of total adverse events (AEs) and serious AEs will be described and documented. Based on an alpha = 0.05 level of significance, a power of 85%, a 15% difference in the culture conversion rate after 2 months between the control arm and experimental arm 1 (75% vs. 90%), a 10% default (loss to follow-up) rate, and a 10% culture failure, the required number per arm was calculated to be 143 (429 in total). DISCUSSION: This trial will reveal the effectiveness and safety of 2 or 4 weeks of use of linezolid instead of Ethambutol for patients with drug-susceptible pulmonary tuberculosis. If a new regimen including linezolid shows a higher culture conversion rate by week 8, and is safe, it could be tested as a 4-month antituberculosis treatment regimen in the future. TRIAL REGISTRATION: ClincalTrials.gov, NCT01994460 . Registered on 13 November 2013.

Primary ethambutol resistance among Iranian pulmonary tuberculosis patients: a systematic review.[Pubmed:28149517]

Ther Adv Infect Dis. 2016 Oct;3(5):133-138.

INTRODUCTION: Ethambutol (EMB) is an anti-mycobacterial agent that is most commonly used in combination with other anti-tuberculosis (TB) drugs in the treatment of TB. Studies have shown that primary resistance rates of Mycobacterium tuberculosis to EMB vary widely, that is, from 1% to as high as 14%. In this study, we aimed to determine the exact prevalence of primary EMB resistance among pulmonary TB cases. METHODS: Several databases, including Medline, Embase, and Iranian databases, were searched from March 2000 to January 2016 to identify studies addressing EMB-resistant TB in Iran. Comprehensive meta-analysis (V2.2, Biostat) software was used to analyze the data. RESULTS: Of the 112 records identified from the databases, 10 studies fulfilled the eligibility criteria. The pooled prevalence of primary EMB-resistant TB was estimated at 4.2% [95% confidence interval (CI) 1.8-9.0]. No evidence of publication bias was observed among the included studies (p = 0.4 for Begg rank correlation analysis; p = 0.2 for Egger weighted regression analysis). CONCLUSION: Results of systematic review and meta-analyses indicated that effective strategies to minimize the acquired drug resistance, to improve the drug susceptibility testing (DST) capability, and to control the transmission of resistance should be attached importance for control of TB in Iran.

Description

Ethambutol is a bacteriostatic antimycobacterial agent, which obstructs the formation of cell wall by inhibiting arabinosyl transferases.

Keywords:

Ethambutol,74-55-5,Emb,Natural Products,Antibiotic, buy Ethambutol , Ethambutol supplier , purchase Ethambutol , Ethambutol cost , Ethambutol manufacturer , order Ethambutol , high purity Ethambutol

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: